We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session. This change lagged the S&P 500's 0.02% gain on the day.
Coming into today, shares of the company had gained 17.49% in the past month. In that same time, the Medical sector gained 1.17%, while the S&P 500 gained 0.04%.
Wall Street will be looking for positivity from CRSP as it approaches its next earnings report date. On that day, CRSP is projected to report earnings of $4.19 per share, which would represent year-over-year growth of 422.31%. Meanwhile, our latest consensus estimate is calling for revenue of $678.05 million, up 1695012.5% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.66 per share and revenue of $570.12 million, which would represent changes of +112.48% and +79194.43%, respectively, from the prior year.
Any recent changes to analyst estimates for CRSP should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.12% higher. CRSP currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that CRSP has a Forward P/E ratio of 180.33 right now. For comparison, its industry has an average Forward P/E of 24.22, which means CRSP is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 212, putting it in the bottom 17% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session. This change lagged the S&P 500's 0.02% gain on the day.
Coming into today, shares of the company had gained 17.49% in the past month. In that same time, the Medical sector gained 1.17%, while the S&P 500 gained 0.04%.
Wall Street will be looking for positivity from CRSP as it approaches its next earnings report date. On that day, CRSP is projected to report earnings of $4.19 per share, which would represent year-over-year growth of 422.31%. Meanwhile, our latest consensus estimate is calling for revenue of $678.05 million, up 1695012.5% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.66 per share and revenue of $570.12 million, which would represent changes of +112.48% and +79194.43%, respectively, from the prior year.
Any recent changes to analyst estimates for CRSP should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.12% higher. CRSP currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that CRSP has a Forward P/E ratio of 180.33 right now. For comparison, its industry has an average Forward P/E of 24.22, which means CRSP is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 212, putting it in the bottom 17% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.